Rational Pharmacotherapy in Cardiology

Advanced search


Full Text:


The review focuses on the impairment of the carotid, coronary arteries and lower-extremity arterial disease. Systemic involvement of various vascular beds in atherogenesis is emphasized. Epidemiological characteristics of morbidity and mortality from the main clinical manifestations of atherosclerosis - ischemic stroke, ischemic heart disease and lower-extremity arterial disease are given. The current principles of drug therapy are considered from the point of view of improving the prognosis and eliminating ischemia. The basic positions of International and Russian clinical recommendations on the management of patients with the presence of certain clinical manifestations of atherosclerosis are discussed. Detailed administration schemes and the preferred doses of statins and antiplatelet agents depending on the localization of atherosclerotic lesion and the severity of stenosis are described. The target blood lipids levels in the treatment with statins are given. The advantages of statins as drugs that reduce the risk of cardiovascular complications are presented. Current data on the pattern of antiplatelet use, including acetylsalicylic acid, in individuals with clinical manifestations of atherosclerosis are given. The principal tactic of dual antiplatelet therapy and schemes of its use in patients undergoing percutaneous coronary intervention, coronary artery bypass surgery and in individuals with a history of acute coronary disorders are considered.

About the Authors

O. D. Ostroumova
A.I. Evdokimov Moscow State University of Medicine and Dentistry; I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

MD, PhD, Professor, Chair of Faculty Therapy and Occupational Diseases, Delegatskaya ul. 20-1, Moscow, 127473;

Professor, Chair of Clinical Pharmacology and Propaedeutics of Internal Diseases, Trubetskaya ul. 8, Moscow, 119991

A. I. Kochetkov
A.I. Evdokimov Moscow State University of Medicine and Dentistry
Russian Federation

MD, PhD, Assistant, Chair of Faculty Therapy and Occupational Diseases,

Delegatskaya ul. 20-1, Moscow, 127473

N. Yu. Voevodina
E.O. Mukhin Municipal Clinical Hospital
Russian Federation

MD, PhD, Deputy Chief Medical Officer,

Federativnii prospekt 17, Moscow, 111399

S. S. Sharonova
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

4-Year Student,

Trubetskaya ul. 8, Moscow, 119991


1. Herrington W., Lacey B., Sherliker P., et al. Epidemiology of Atherosclerosis and the Potential to Reduce the Global Burden of Atherothrombotic Disease. Circ Res. 2016;118(4):535-46. doi: 10.1161/CIRCRESAHA.115.307611.

2. Aziz M., Yadav K.S. Pathogenesis of Atherosclerosis. A Review. Medical & Clinical Reviews. 2016;2(3):22. doi: 10.21767/2471-299X.100031.

3. Langhoff R. Carotid stenosis - basing treatment on individual patients' needs. Optimal medical therapy alone or accompanied by stenting or endarterectomy. Vasa. 2018;47(1):7-16. doi: 10.1024/0301-1526/a000668.

4. Marulanda-Londoño E., Chaturvedi S. Stroke due to large vessel atherosclerosis: Five new things. Neurology: Clinical Practice. 2016;6(3):252-8. doi:10.1212/CPJ.0000000000000247.

5. Russia Today. To beat off a blow: the Ministry of Health announced a reduction in deaths from stroke. [cited by 21.06.2018]. Available from: (In Russ.) [Russia Today. Отбить удар: в Минздраве заявили о снижении смертности от инсульта. [цитировано 21.06.2018]. Доступно на:].

6. Tanashyan M.M., Lagoda O.V., Klimenko I.S., et al. Asymptomatic stenosis of carotid arteries: novel view on the problem. Annali Klinicheskoy I Eksperimental’noy Nevrologii. 2009;3(2):17-20. (In Russ.) [Танашян М.М., Лагода О.В., Клименко И.С., и др. Асимптомные стенозы сонных артерий: еще один взгляд на проблему. Анналы Клинической и Экспериментальной Неврологии. 2009;3(2):17-20].

7. O’Brien M., Chandra A. Carotid revascularization: risks and benefits. Vascular Health and Risk Management. 2014;10:403-16. doi:10.2147/VHRM.S48923.

8. Inzitari D., Eliasziw M., Gates P., et al. The causes and risk of stroke in patients with asymptomatic internal-carotid-artery stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med. 2000;342(23):1693-700. doi: 10.1056/NEJM200006083422302.

9. Liapis C., Kakisis J., Kostakis A. Carotid stenosis: Factors affecting symptomatology. Stroke. 2001;32:2782-6.

10. Johansson E., Cuadrado-Godia E., Hayden D., et al. Recurrent stroke in symptomatic carotid stenosis awaiting revascularization: A pooled analysis. Neurology. 2016;86(6):498-504. doi: 10.1212/WNL.0000000000002354.

11. Aboyans V., Ricco J.B., Bartelink M.E.L., et al.; ESC Scientific Document Group. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018;39(9):763-816. doi: 10.1093/eurheartj/ehx095.

12. Wilterdink J.I., Easton J.D. Vascular event rates in patients with atherosclerotic cerebrovascular disease. Arch Neurol. 1992;49:857-63. doi:10.1001/archneur.1992.00530320089016.

13. Kannel W.B. Risk factors for atherosclerotic cardiovascular outcomes in different arterial territories. J Cardiovasc Risk. 1994;1(4):333-9.

14. Ezhov M.V., Sergienko I.V., Aronov D.M., et al. Diagnostics and correction of lipid metabolism disorders in order to prevent and treat atherosclerosis. Russian recommendations VI revision. Ateroskleroz i Dislipidemii. 2017;3:5-22. (In Russ.) [Ежов М.В., Сергиенко И.В., Аронов Д.М., и др. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации. VI пересмотр, 2017 год. Атеросклероз и Дислипидемии. 2017;3:5-22].

15. Catapano A.L., Graham I., De Backer G., et al.; ESC Scientific Document Group. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J. 2016;37(39):2999-3058. doi: 10.1093/eurheartj/ehw272.

16. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7-22. doi: 10.1016/S0140-6736(02)09327-3.

17. Amarenco P., Labreuche J., Lavallee P., Touboul P.J. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke. 2004;35:2902-9. doi: 10.1161/01.STR.0000147965.52712.fa.

18. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71-86. doi: 10.1136/bmj.324.7329.71.

19. Pickett C.A., Jackson J.L., Hemann B.A., Atwood J.E. Carotid bruits as a prognostic indicator of cardiovascular death and myocardial infarction: a meta-analysis. Lancet. 2008;371(9624):1587-94. doi: 10.1016/S0140-6736(08)60691-1.

20. Task Force Members, Montalescot G., Sechtem U., Achenbach S., et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34(38):2949-3003. doi: 10.1093/eurheartj/eht296.

21. Kandaswamy E., Zuo L. Recent Advances in Treatment of Coronary Artery Disease: Role of Science and Technology. Int J Mol Sci. 2018;19(2). pii: E424. doi: 10.3390/ijms19020424.

22. News. Mortality from heart and vascular disease has reached a minimum since 2010. [cited by 21.06.2018]. Available from: (In Russ.) [Известия. Смертность от болезней сердца и сосудов достигла минимума c 2010 года. [цитировано 21.06.2018]. Доступно на:].

23. Patti G., Cannon C.P., Murphy S.A., et al. Clinical benefit of statin pretreatment in patients undergoing percutaneous coronary intervention: a collaborative patient-level meta-analysis of 13 randomized studies. Circulation. 2011;123(15):1622-32. doi: 10.1161/CIRCULATIONAHA.110.002451.

24. Gandhi S., Mosleh W., Abdel-Qadir H., Farkouh M.E. Statins and contrast-induced acute kidney injury with coronary angiography. Am J Med. 2014;127(10):987-1000. doi: 10.1016/j.amjmed.2014.05.011.

25. Valgimigli M., Bueno H., Byrne R.A., et al.; ESC Scientific Document Group; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39(3):213-60. doi: 10.1093/eurheartjehx419.

26. Ibanez B., James S., Agewall S., et al.; ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119-77. doi: 10.1093/eurheartjehx393.

27. Roffi M., Patrono C., Collet J.P., et al.; ESC Scientific Document Group. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(3):267-315. doi: 10.1093/eurheartj/ehv320.

28. Criqui М.Н., Aboyans V. Epidemiology of Peripheral Artery Disease. Circ Res. 2015;116:1509-26. doi: 10.1161/CIRCRESAHA.116.303849.

29. Hirsch A.T., Criqui M.H., Treat-Jacobson D., et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001;286(11):1317-24. doi:10.1001/jama.286.11.1317.

30. Aung P.P., Maxwell H.G., Jepson R.G., et al. Lipid-lowering for peripheral arterial disease of the lower limb.CochraneDatabase Syst Rev.2007;(4):CD000123. doi:10.1002/14651858.CD000123.pub2.

31. Heart Protection Study Collaborative Group. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg. 2007;45:645-54. doi: 10.1016/j.jvs.2006.12.054.

32. Antoniou G.A., Fisher R.K., Georgiadis G.S., et al. Statin therapy in lower limb peripheral arterial disease: Systematic review and meta-analysis. Vascul Pharmacol. 2014;63(2):79-87. doi: 10.1016/j.vph.2014.09.001.

33. Kumbhani D.J., Steg P.G., Cannon C.P., et al.; REACH Registry Investigators. Statin therapy and longterm adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry. Eur Heart J. 2014;35(41):2864-72. doi: 10.1093/eurheartj/ehu080.

34. Westin G.G., Armstrong E.J., Bang H., et al. Association between statin medications and mortality, major adverse cardiovascular event, and amputation-free survival in patients with critical limb ischemia. J Am Coll Cardiol. 2014;63:682-90. doi: 10.1016/j.jacc.2013.09.073.

35. Vogel T.R., Dombrovskiy V.Y., Galiñanes E.L., Kruse R.L. Preoperative statins and limb salvage after lower extremity revascularization in the Medicare population. Circ Cardiovasc Interv. 2013 Dec;6(6):694-700. doi: 10.1161/CIRCINTERVENTIONS.113.000274.

36. Mohler E.R., Hiatt W.R., Creager M.A. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation. 2003;108:1481-6. doi: 10.1161/01.CIR.0000090686.57897.F5.

37. Levine G.N., Bates E.R., Bittl J.A., et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2016;134:e123-e155. doi: 10.1161/CIR.0000000000000404.

38. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996;348(9038):1329- 39. doi: 10.1016/S0140-6736(96)09457-3.

39. Jones P.H., Hunninghake D.B., Ferdinand K.C., et al.; Statin Therapies for Elevated Lipid Levels Compared Across Doses to Rosuvastatin Study Group. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial. Clin Ther. 2004;26(9):1388-99. doi: 10.1016/j.clinthera.2004.09.006.

40. Betteridge D.J., Gibson J.M., Sager P.T. Comparison of effectiveness of rosuvastatin versus atorvastatin on the achievement of combined C-reactive protein (< 70 mg/dl) targets in patients with type 2 diabetes mellitus (from the ANDROMEDA study). Am J Cardiol. 2007;100(8):1245-8. doi: 10.1016/j.amjcard.2007.05.044.

41. Leiter L.A., Rosenson R.S., Stein E., et al.; POLARIS study investigators. Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: results of the POLARIS study. Atherosclerosis. 2007;194(2):e154-64. doi: 10.1016/j.atherosclerosis.2006.12.001.

42. Wolffenbuttel B.H., Franken A.A., Vincent H.H.; Dutch Corall Study Group. Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes -- CORALL study. J Intern Med. 2005;257(6):531-9. doi: 10.1111/j.1365-2796.2005.01499.x.

43. Berne C., Siewert-Delle A.; URANUS study investigators. Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study. Cardiovasc Diabetol. 2005;4:7. doi: 10.1186/1475-2840-4-7.

44. Mancia G., Fagard R., Narkiewicz K., et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281-357. doi:10.1093/eurheartj/eht151.

For citation:

Ostroumova O.D., Kochetkov A.I., Voevodina N.Yu., Sharonova S.S. THE POSSIBILITIES OF USING A NEW FIXED-DOSE COMBINATION OF ROSUVASTATIN AND ACETYLSALICYLIC ACID: FOCUS GROUPS OF PATIENTS. Rational Pharmacotherapy in Cardiology. 2018;14(3):425-433. (In Russ.)

Views: 725

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)